MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
Portfolio Companies: Laidlaw
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)*
Organization & Developments: Aldeyra
Parents
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)*
Children
2018: 2 Small Biotechs To Consider - Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)
2018: Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy - Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)
2018: Revisiting Aldeyra Pharmaceuticals - Bret Jensen
2021: Strong Reproxalap Results Give Aldeyra A Good Balance Of Risk Versus Potential Reward
2022: Aldeyra Therapeutics: Dry Eye Is Just The Beginning For Novel MOA_seekingalpha.com
2022: Aldeyra Therapeutics: NDA Submission For Large Multi-Billion Dollar Market_seekingalpha.com
2023: Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study
2023: Buy Aldeyra Therapeutics For Consecutive Runups_ seekingalpha.com
2024: Aldeyra resubmits reproxalap NDA for treatment of dry eye
2024: Aldeyra shows FDA-rejected reproxalap improves eye discomfort in new phase 3 study
2024: Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
2024: Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership
2024: Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory
2024: Aldeyra Therapeutics: Key Inflection Point Ahead
2024: Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
2024: Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects_seekingalpha.com
2024: Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects_ seekingalpha
2025:Aldeyra Therapeutics Is Severely Undervalued Before PDUFA
Jumps
*Key People: Aldeyra
Finance & Acquisitions: Aldeyra